

ondine



For Immediate Release

Ondine Obtains Health Canada License for Endodontic Use (Root Canal Therapy)

Additional indication for Periowave™

VANCOUVER, BC, January 25, 2007 – ONDINE BIOPHARMA CORPORATION (TSX: OBP, AIM: OBP) (the “Company”) announces that it has received a Health Canada license for the endodontic (root canal) application of its Periowave™ Photodisinfection system.

“This new license will pave the way for further adoption by the dental community of our safe and effective disinfection technology,” said Carolyn Cross, President and CEO of Ondine Biopharma. “Our endodontic treatment kit, expected to be released in the quarters ahead, is fully compatible with the existing Periowave™ system that is currently available in Canada for the treatment of chronic periodontitis (gum disease). Ondine intends to continue to develop other indications for the Periowave™ photodisinfection system.”

About Endodontics

Endodontics is the branch of dentistry concerned with the treatment of the tooth pulp and tissues surrounding the root of a tooth. Pulp decay is caused by a bacterial invasion of the pulp chamber. If left untreated, the bacterial infection may spread from the root to the surrounding bone causing tissue breakdown and severe pain. The most common procedure in endodontics is root canal therapy, involving the removal of diseased pulp tissue and replacement with a sealing compound. Unsuccessful root canal therapy often requires removal of the tooth to reduce pain and other symptoms. In 2005, over 14.7 million endodontic procedures were performed in the US. Photodisinfection provides a means for enhanced disinfection of the root canal prior to sealing the treated tooth.

About Periowave™ and Photodisinfection

Periowave™ is a photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business plc, University College London. Additional information about Periowave™ is available at www.periowave.com.

About Ondine Biopharma Corporation:

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection (PDD) provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. Ondine has developed Periowave™ for the treatment of chronic periodontitis and endodontics, and is extending its platform technology into other applications both within and outside the oral cavity.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Redmond, Washington, USA, a sales and marketing subsidiary in York, Pennsylvania, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

For further information please contact:

Carolyn Cross	Christina Bessant
President and Chief Executive Officer	Investor Relations
Ondine Biopharma Corporation	The Equicom Group Inc.
(604) 669-0555	(416) 815-0700 ext. 269
ccross@ondinebiopharma.com	cbessant@equicomgroup.com